Antisense oligonucleotide (ASO)-based therapeutics are becoming more and more popular as evidenced by the recent increase in market approvals and high value partnering transactions. ASOs fill a position not or insufficiently addressed by more traditional approaches. Recognizing this is what motivated us to develop our 3rd generation antisense platform LNAplus™. We concentrate on targets that are either considered as undruggable by conventional approaches or where we believe that Secarna’s LNAplus™-based ASOs have the potential to demonstrate superior safety and efficacy over other modalities.
We have established a successful partnership model complementing our molecule design and selection process. In the past, we have engaged in collaborations with internationally renowned centers of excellence in academia as well as leading industry partners.
Our leadership team consists of biotechnology and pharmaceutical industry experts who are recognized for their contributions in the development of novel antisense therapies and bringing new, safe and efficacious treatments to patients.
Before joining Secarna as CEO in December 2020, Alexander was CEO and Chairman at Omeicos Ophthalmics Inc, Cambridge, MD, US and served as CDO and Managing Director in the Berlin, Germany based sister company Omeicos Therapeutics GmbH.
During the last 15 years of his more than 30 years in the industry, Alexander held C-level positions at leading global companies as Sun Pharmaceuticals and Merz Pharmaceuticals. Alexander is also co-founder and Executive Chairman of US-based Galimedix Therapeutics. Alexander studied medicine at Gutenberg University in Mainz, Germany where he gained his doctor's degree in experimental pharmacology. He also holds a degree in computer science and lectures pharmacoeconomics.
Frank joined Secarna in 2015 as its Chief Scientific Officer. He is an expert in discovery and development of antisense oligonucleotides.
Frank’s therapeutic expertise is rooted in the fields of oncology and metabolic diseases. He has profound knowledge in conceptualizing, developing and evaluating ASO-based, targeted therapies, playing a central role in establishing new, high value ASO pipelines in the course of his career. Before joining Secarna, Frank worked in scientific leadership positions at Antisense Pharma/Isarna Therapeutics and The Genetics Company.
Frank is an active contributor to the international scientific and biopharmaceutical discovery and development community and his and his team’s work is recognized at international conferences and in major peer-reviewed publications.
Richard joined Secarna in 2016 and contributed to building up Secarna’s in-house pipeline, ASO platform and partnering business. He has taken roles of increasing responsibility since. Prior to his current position as Chief Research Officer, Richard has supported Secarna as Head of Research and Platform Development.
Richard has over 15 years of experience in the field of immunology/immunooncology and has focused his research on the identification of novel therapeutic approaches to treat patients with cancer. With his doctoral studies and a Postdoc in translational immunotherapy at the Klinikum rechts der Isar (TU München), he has built extensive knowledge in this field.
Richard studied biology at Regensburg University and holds a doctor’s degree in immunology. He has a track record in bringing novel discoveries to the scientific community, with several approved patents and 15+ peer-reviewed publications.
At Secarna, we enjoy a modern corporate culture and foster an open-minded, diverse and creative work environment where our team members can contribute and thrive. Together, we work towards our mission to discover and develop the next generation antisense oligonucleotide therapeutics.
We always welcome new ideas, fresh perspectives and look forward to connecting with exceptional scientific talents with a strong entrepreneurial spirit inspired by our Company’s mission to discover and develop the next generation antisense oligonucleotide therapeutics.